Starpharma Holdings’ Shares Surged Over 7% On ASX Post First VivaGel BV Launch Announcement

Starpharma Holdings’ Shares Surged Over 7% On ASX Post First VivaGel BV Launch Announcement

Starpharma Holdings Limited (ASX: SPL) announced that they have successfully launched VivaGel® BV (an Australian innovation) in Australia through Aspen Pharmacare (Aspen) as Fleurstat BVgel. This is the first launch and distribution of product across Australia, following which further launches by Mundipharma are expected in Europe in May/June this year.

The product is a non-antibiotic therapy for the treatment of bacterial vaginosis (BV) and relief of symptoms, where bacterial vaginosis is the most common vaginal condition (twice as common as thrush). Bacterial vaginosis often has significant social impacts on women as it causes unpleasant vaginal odour and discharge symptoms. It has been associated with other serious reproductive health-related medical problems.

Fleurstat BVgel is being marketed in Australia by Aspen as a non-antibiotic therapy and only treatment for bacterial vaginosis available over-the-counter (OTC) at pharmacies, without the need for a prescription.

Starpharma’s Chief Executive Officer, Dr. Jackie Fairley, stated that they are excited to achieve the important milestone of the first launch of VivaGel® BV in the world, in collaboration with their Australian partner, Aspen. The product is marketed as Fleurstat BVgel and is a real success story of an Australian innovation, which is rare to have a global healthcare product developed by an Australian company all the way from concept to commercialisation.

Head of Nutritionals & Consumer OTC (Over-the-Counter), Aspen Australia, Rob Barnes stated that they are excited to be the first company in the world to launch and make Fleurstat BVgel available to Australian women who would be able to purchase a BV product over-the-counter in pharmacies.

In a previous update, Starpharma Holdings announced its meeting with US FDA to clarify all the details related to the approval of VivaGel® BV in the US. The meeting was attended by senior officials of the company along with key leaders in BV and FDA regulatory consultants.

Sponsored ad by Kalkine

In another announcement, the company presented its operational highlights at Goldman Sachs Emerging Leaders Conference. The group noted that it comprises a deep portfolio of high-value global products with the potential to significantly improve patient outcomes, mainly VivaGel® portfolio and DEP® Drug delivery portfolio. Under VivaGel®, it has VivaGel® BV,  VivaGel®condom, and SPL7013 ophthalmic. Under Internal DEP®, it has DEP® docetaxel, DEP® cabazitaxel, DEP® irinotecan, other targeted DEP®. Under partnered DEP®, it has AZ DEP® AZD0466, AZ #2 DEP® candidate, AZ #3 DEP® candidate, Antibody Drug Conjugate (ADC) #1 and #2.

On the stock information front, at the time of writing (on April 16, 2019, AEST: 02:00 PM) the stock of Starpharma Holdings was trading at $1.165, up 7.87% with a market capitalisation of ~$401.43 million. Today, it touched a day’s high at $1.177 and day’s low at $1.085, with a daily volume of more than 598,984. Its 52 weeks high stands at $1.662 and 52 weeks low at $0.87, with an average volume of 282,820. Its absolute return for five years, one year, six months, and three months are 44.16%, -1.77%, -25.25%, and 0.91%, respectively.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Facebook Comments

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here